Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 216,126,704
  • Shares Outstanding, K 5,947,350
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 1.00
  • Price/Sales 4.09
  • Price/Cash Flow 10.75
  • Price/Book 3.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.19 +2.23%
on 09/27/17
36.60 -1.69%
on 10/12/17
+0.62 (+1.75%)
since 09/15/17
3-Month
32.32 +11.32%
on 08/21/17
36.60 -1.69%
on 10/12/17
+2.55 (+7.63%)
since 07/14/17
52-Week
29.83 +20.62%
on 11/03/16
36.60 -1.69%
on 10/12/17
+3.32 (+10.17%)
since 10/14/16

Most Recent Stories

More News
Pharma Industry Outlook - October 2017

Pharma Industry Outlook - October 2017

TEVA : 14.71 (-1.80%)
GILD : 79.95 (-1.50%)
AMGN : 181.90 (-0.61%)
PFE : 35.98 (-0.99%)
J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.

CELG : 136.71 (+0.18%)
JNJ : 136.12 (-0.23%)
ABBV : 91.04 (+0.41%)
PFE : 35.98 (-0.99%)
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE:PFE) today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically...

PFE : 35.98 (-0.99%)
5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings

The pharma/biotech sector has a number of things going in its favor.

AZN : 34.65 (+0.12%)
LLY : 85.95 (-0.69%)
PFE : 35.98 (-0.99%)
GSK : 40.86 (-0.37%)
BMY : 63.65 (-2.51%)
Spin-Off ETF: Can the Outperformance Continue?

Spin-off activities picked up pace in the United States.

PYPL : 67.31 (-1.97%)
SPUN : 23.80 (-0.75%)
DF : 10.56 (-0.94%)
ABT : 54.63 (-0.04%)
EBAY : 37.77 (-1.51%)
CSD : 51.63 (unch)
HON : 143.75 (+0.27%)
ABBV : 91.04 (+0.41%)
WWAV : 56.24 (+0.02%)
PFE : 35.98 (-0.99%)
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

AERI : 64.05 (+4.23%)
ACRX : 1.95 (-8.24%)
MRK : 63.34 (-0.08%)
LLY : 85.95 (-0.69%)
AGN : 198.41 (-3.46%)
PFE : 35.98 (-0.99%)
BMY : 63.65 (-2.51%)
Spin-Off ETF: Can the Outperformance Continue?

Spin-off activities picked up pace in the United States.

PYPL : 67.31 (-1.97%)
SPUN : 23.80 (-0.75%)
DF : 10.56 (-0.94%)
ABT : 54.63 (-0.04%)
EBAY : 37.77 (-1.51%)
CSD : 51.63 (unch)
HON : 143.75 (+0.27%)
ABBV : 91.04 (+0.41%)
WWAV : 56.24 (+0.02%)
PFE : 35.98 (-0.99%)
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib

Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.

MRK : 63.34 (-0.08%)
LLY : 85.95 (-0.69%)
RHHBY : 31.1800 (-0.73%)
PFE : 35.98 (-0.99%)
Corporate News Blog - Pharma Giant Pfizer Mulling Divestment of Consumer Healthcare Business

LONDON, UK / ACCESSWIRE / October 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Pfizer Inc. (NYSE: PFE), following which we have published a...

PFE : 35.98 (-0.99%)
U.S. FDA Approves LYRICA(R) CR (pregabalin) Extended-Release Tablets CV

Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved LYRICA(R) CR (pregabalin) extended-release tablets CV as once-daily therapy...

PFE : 35.98 (-0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 36.71
1st Resistance Point 36.35
Last Price 35.98
1st Support Level 35.75
2nd Support Level 35.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart